Abstract
BackgroundPatients with critical limb ischemia (CLI) have a high risk to develop cardiovascular events (CVE). We hypothesized that in CLI patients platelets would display increased baseline activation and reactivity.ObjectivesWe investigated baseline platelet activation and platelet reactivity in patients with CLI.Patients/MethodsIn this study baseline platelet activation and platelet reactivity in response to stimulation of all major platelet activation pathways were determined in 20 CLI patients (11 using aspirin and 9 using vitamin K-antagonists) included in the Juventas-trial (clinicaltrials.gov NCT00371371) and in 17 healthy controls. Platelet activation was quantified with flow cytometric measurement of platelet P-selectin expression and fibrinogen binding.ResultsCLI patients not using aspirin showed higher baseline platelet activation compared to healthy controls. Maximal reactivity to stimulation of the collagen and thrombin activation pathway was decreased in CLI patients compared to healthy controls. In line, attenuated platelet reactivity to stimulation of multiple activation pathways was associated with several traditional risk factors for cardiovascular disease.ConclusionsBaseline platelet activation was increased in CLI patients, whereas the reactivity of circulating platelets to several stimulatory agents is decreased. Reactivity of platelets was inversely correlated with cardiovascular risk factors.
Highlights
Critical Limb Ischemia (CLI), the most advanced stage of peripheral artery disease (PAD), is characterized by ischemic rest pain or tissue loss as well as a profound risk for cardiovascular complications and mortality [1,2]
CLI patients not using aspirin showed higher baseline platelet activation compared to healthy controls
Maximal reactivity to stimulation of the collagen and thrombin activation pathway was decreased in CLI patients compared to healthy controls
Summary
Critical Limb Ischemia (CLI), the most advanced stage of peripheral artery disease (PAD), is characterized by ischemic rest pain or tissue loss as well as a profound risk for cardiovascular complications and mortality [1,2]. Antiplatelet therapy reduces the risk for future cardiovascular events (CVE) in patients with previous cardiovascular disease and is the cornerstone of medical therapy in PAD [8]. To properly interpret platelet reactivity tests and employ effective interventions, more detailed data on platelet function in patients with severe PAD is mandatory. Patients with critical limb ischemia (CLI) have a high risk to develop cardiovascular events (CVE). We hypothesized that in CLI patients platelets would display increased baseline activation and reactivity
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
